Barclays (LON:BARC) analyst Peter Lawson maintained a Buy rating on MacroGenics (NASDAQ:MGNX) on Wednesday, setting a price target of $35, which is approximately 61.51% above the present share price of $21.67.
Lawson expects MacroGenics to post earnings per share (EPS) of -$0.66 for the fourth quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in MacroGenics, with an average price target of $40.8.
The analysts price targets range from a high of $50 to a low of $35.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $30.76 million and a net profit of -$40.28 million. The company's market cap is $1.32 billion.
According to TipRanks.com, Barclays analyst Peter Lawson is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 7.3% and a 45.35% success rate.
MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. 2. Its product pipeline includes Margetuximab, Flotetuzumab, Enoblituzumab, MGA012, MGD013, MGD019, MGD009, MGC018, and MGD007 for oncology; and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.